Literature DB >> 7586507

Developmental changes of apolipoprotein E immunoreactivity in Down syndrome brains.

Y Arai1, M Mizuguchi, K Ikeda, S Takashima.   

Abstract

The temporal profile of apolipoprotein-E (apo-E) expression was investigated immunohistochemically in the brains of Down syndrome patients and of normal controls. The number of apo-E immunoreactive astrocytes in the frontal cortex was larger in Down syndrome patients than in controls from 7 months to 24 years of age. It suggests that apo-E producing astrocytes in the early phase of pathological process lead to presenile dementia in Down syndrome patients. In contrast, the number in the white matter was smaller in Down syndrome patients from 28 gestational weeks to 5 years. Apo-E immunoreactive senile plaques were noted in Down syndrome brains from the age of 25 years, while APP immunoreactivity was first noted in senile plaques at the age of 32 years.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586507     DOI: 10.1016/0165-3806(95)00066-m

Source DB:  PubMed          Journal:  Brain Res Dev Brain Res        ISSN: 0165-3806


  4 in total

1.  Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease.

Authors:  C Russo; G Angelini; D Dapino; A Piccini; G Piombo; G Schettini; S Chen; J K Teller; D Zaccheo; P Gambetti; M Tabaton
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

Review 2.  APOE mediated neuroinflammation and neurodegeneration in Alzheimer's disease.

Authors:  Samira Parhizkar; David M Holtzman
Journal:  Semin Immunol       Date:  2022-02-26       Impact factor: 10.671

Review 3.  Developmental Neuropathology and Neurodegeneration of Down Syndrome: Current Knowledge in Humans.

Authors:  Zinnat Hasina; Nicole Wang; Chi Chiu Wang
Journal:  Front Cell Dev Biol       Date:  2022-05-23

Review 4.  Astroglial and microglial pathology in Down syndrome: Focus on Alzheimer's disease.

Authors:  Octavio García; Lisi Flores-Aguilar
Journal:  Front Cell Neurosci       Date:  2022-09-20       Impact factor: 6.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.